Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Gains Budget Increase In FY 2017…And Not Through Fees

Executive Summary

Omnibus legislation to fund the federal government for the remainder of FY 2017 includes a switch from what has been a growing trend of FDA's increasing reliance on industry user fees as opposed to congressional appropriations. Non-user-fee budget authority will grow, while fee amounts dropped for the fiscal year.

You may also be interested in...

Gottlieb Becomes FDA Commissioner With Immediate Issues Pending

Confirmation comes with fewest votes of any recent commissioner as FDA dealing with budget, user fees and other issues.

FDA 'Cures' Fund Breakdown: Breakthrough Devices, HDEs, IRB Flexibility And More

FDA's device center 'has a lot of work ahead of us,' to implement not only the 21st Century Cures Act, but also maintain performance goals for device and drug reviews, speakers said at a Food Drug Law Institute meeting May 5. The agency released a proposed work plan for use of 'Cures' Innovation Account funds, with dollars detailed for the device side on breakthrough devices, humanitarian device exemptions, and least burdensome device provisions, among others, as spelled out for use at a May 8-9 Science Board meeting.

FDA's Government Shutdown Plan Ready, Just In Case

With a little more than a week left for Congress to extend government funding, US FDA and HHS plan for furloughs should no new appropriations be enacted.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts